Duration of immune protection after hepatitis B vaccine in newborns from HBsAg-positive carrier mothers.
A group of 43 healthy neonates born from HBsAg-positive mothers were evaluated for the presence of protective HBsAb titre after administration of hepatitis B plasma-derived vaccine and hepatitis B hyperimmune-globulin. At 36 months of life we found that a significant number of children had a low HBsAb serum level. This suggests that a close serologic follow-up is necessary to evaluate the optimal timing for the administration of a booster dose of the vaccine.
Belloni
C
C
Division of Neonatal Intensive Care-IRCCS-Policlinico S. Matteo, Pavia, Italy.
Orsolini
P
P
Soldini
L
L
Campisi
D
D
Chiesa
A
A
Ciceri
R
R
Filice
G
G
D002353:Carrier State / Q000276:immunology*; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007231:Infant, Newborn; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D016756:Immunoglobulins, Intravenous; D014761:Viral Hepatitis Vaccines